REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION
Introduction: Discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often results in rebound obesity and excessive weight regain. This review explores the physiological, psychological, and behavioural factors contributing to weight regain after the discontinuation of GLP-1 RAs. Me...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Education in Action Club
2025-07-01
|
| Series: | Global Journal of Public Health Medicine |
| Subjects: | |
| Online Access: | https://www.gjphm.org/index.php/gjphm/article/view/336 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234158249836544 |
|---|---|
| author | Zainab M. Al-Shammaa Heba M. Attash Luma Al-Obaidy |
| author_facet | Zainab M. Al-Shammaa Heba M. Attash Luma Al-Obaidy |
| author_sort | Zainab M. Al-Shammaa |
| collection | DOAJ |
| description | Introduction: Discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often results in rebound obesity and excessive weight regain. This review explores the physiological, psychological, and behavioural factors contributing to weight regain after the discontinuation of GLP-1 RAs. Methods: This narrative review involved a review of literature published in PubMed, Scopus, Embase, Web of Science, and Google Scholar. The search for peer-reviewed literature in English started on 8 March 2025 and was repeated for updates on 25 March 2025. Results: The literature search identified only five studies that examined weight regain following the discontinuation of GLP-1 receptor agonists. These studies found that some users of these agents had regained the weight they lost before upon discontinuing GLP-1RAs. The proposed mechanism for this phenomenon is that abrupt cessation of appetite inhibition induced by GLP-1RAs leads to a surge in hunger, reduced energy expenditure, and fat mass gain. Psychological factors, like emotional overeating and dependence on the therapy, further exacerbate rebound. Clinical studies show significant weight regain after stopping semaglutide, liraglutide, or tirzepatide. Conclusion: This review focuses on the complex phenomenon of rebound obesity that may develop upon GLP-1 RAs discontinuation, emphasizing the need for comprehensive strategies to manage weight regain. Potential approaches include gradual dose reduction, combination therapies, and lifestyle interventions to mitigate weight regain. |
| format | Article |
| id | doaj-art-70d41ee48c914bdab65b32965fe826a0 |
| institution | Kabale University |
| issn | 2664-4657 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Education in Action Club |
| record_format | Article |
| series | Global Journal of Public Health Medicine |
| spelling | doaj-art-70d41ee48c914bdab65b32965fe826a02025-08-20T04:03:16ZengEducation in Action ClubGlobal Journal of Public Health Medicine2664-46572025-07-017120821510.37557/gjphm.v7i1.336326REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATIONZainab M. Al-Shammaa0Heba M. Attash1Luma Al-Obaidy2College of Pharmacy, University of Mosul, Nineveh, IraqCollege of Pharmacy, University of Mosul, Nineveh, IraqCollege of Pharmacy, University of Mosul, Nineveh, IraqIntroduction: Discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often results in rebound obesity and excessive weight regain. This review explores the physiological, psychological, and behavioural factors contributing to weight regain after the discontinuation of GLP-1 RAs. Methods: This narrative review involved a review of literature published in PubMed, Scopus, Embase, Web of Science, and Google Scholar. The search for peer-reviewed literature in English started on 8 March 2025 and was repeated for updates on 25 March 2025. Results: The literature search identified only five studies that examined weight regain following the discontinuation of GLP-1 receptor agonists. These studies found that some users of these agents had regained the weight they lost before upon discontinuing GLP-1RAs. The proposed mechanism for this phenomenon is that abrupt cessation of appetite inhibition induced by GLP-1RAs leads to a surge in hunger, reduced energy expenditure, and fat mass gain. Psychological factors, like emotional overeating and dependence on the therapy, further exacerbate rebound. Clinical studies show significant weight regain after stopping semaglutide, liraglutide, or tirzepatide. Conclusion: This review focuses on the complex phenomenon of rebound obesity that may develop upon GLP-1 RAs discontinuation, emphasizing the need for comprehensive strategies to manage weight regain. Potential approaches include gradual dose reduction, combination therapies, and lifestyle interventions to mitigate weight regain.https://www.gjphm.org/index.php/gjphm/article/view/336glp-1 receptor agonists, weight regain, rebound obesity, discontinuation, lifestyle interventions |
| spellingShingle | Zainab M. Al-Shammaa Heba M. Attash Luma Al-Obaidy REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION Global Journal of Public Health Medicine glp-1 receptor agonists, weight regain, rebound obesity, discontinuation, lifestyle interventions |
| title | REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION |
| title_full | REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION |
| title_fullStr | REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION |
| title_full_unstemmed | REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION |
| title_short | REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION |
| title_sort | rebound obesity after glp 1 agonists discontinuation |
| topic | glp-1 receptor agonists, weight regain, rebound obesity, discontinuation, lifestyle interventions |
| url | https://www.gjphm.org/index.php/gjphm/article/view/336 |
| work_keys_str_mv | AT zainabmalshammaa reboundobesityafterglp1agonistsdiscontinuation AT hebamattash reboundobesityafterglp1agonistsdiscontinuation AT lumaalobaidy reboundobesityafterglp1agonistsdiscontinuation |